Complete tumor necrosis after neoadjuvant chemotherapy defines good responders in patients with Ewing sarcoma.
Ewing sarcoma
bone tumor
cancer treatment
survival outcomes
tumor necrosis
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
revised:
15
08
2022
received:
13
12
2021
accepted:
22
08
2022
pubmed:
29
10
2022
medline:
15
12
2022
entrez:
28
10
2022
Statut:
ppublish
Résumé
Survival in patients who have Ewing sarcoma is correlated with postchemotherapy response (tumor necrosis). This treatment response has been categorized as the response rate, similar to what has been used in osteosarcoma. There is controversy regarding whether this is appropriate or whether it should be a dichotomy of complete versus incomplete response, given how important a complete response is for in overall survival of patients with Ewing sarcoma. The purpose of this study was to evaluate the impact that the amount of chemotherapy-induced necrosis has on (1) overall survival, (2) local recurrence-free survival, (3) metastasis-free survival, and (4) event-free survival in patients with Ewing sarcoma. In total, 427 patients who had Ewing sarcoma or tumors in the Ewing sarcoma family and received treatment with preoperative chemotherapy and surgery at 10 international institutions were included. Multivariate Cox proportional-hazards analyses were used to assess the associations between tumor necrosis and all four outcomes while controlling for clinical factors identified in bivariate analysis, including age, tumor volume, location, surgical margins, metastatic disease at presentation, and preoperative radiotherapy. Patients who had a complete (100%) tumor response to chemotherapy had increased overall survival (hazard ratio [HR], 0.26; 95% CI, 0.14-0.48; p < .01), recurrence-free survival (HR, 0.40; 95% CI, 0.20-0.82; p = .01), metastasis-free survival (HR, 0.27; 95% CI, 0.15-0.46; p ≤ .01), and event-free survival (HR, 0.26; 95% CI, 0.16-0.41; p ≤ .01) compared with patients who had a partial (0%-99%) response. Complete tumor necrosis should be the index parameter to grade response to treatment as satisfactory in patients with Ewing sarcoma. Any viable tumor in these patients after neoadjuvant treatment should be of oncologic concern. These findings can affect the design of new clinical trials and the risk-stratified application of conventional or novel treatments.
Sections du résumé
BACKGROUND
Survival in patients who have Ewing sarcoma is correlated with postchemotherapy response (tumor necrosis). This treatment response has been categorized as the response rate, similar to what has been used in osteosarcoma. There is controversy regarding whether this is appropriate or whether it should be a dichotomy of complete versus incomplete response, given how important a complete response is for in overall survival of patients with Ewing sarcoma. The purpose of this study was to evaluate the impact that the amount of chemotherapy-induced necrosis has on (1) overall survival, (2) local recurrence-free survival, (3) metastasis-free survival, and (4) event-free survival in patients with Ewing sarcoma.
METHODS
In total, 427 patients who had Ewing sarcoma or tumors in the Ewing sarcoma family and received treatment with preoperative chemotherapy and surgery at 10 international institutions were included. Multivariate Cox proportional-hazards analyses were used to assess the associations between tumor necrosis and all four outcomes while controlling for clinical factors identified in bivariate analysis, including age, tumor volume, location, surgical margins, metastatic disease at presentation, and preoperative radiotherapy.
RESULTS
Patients who had a complete (100%) tumor response to chemotherapy had increased overall survival (hazard ratio [HR], 0.26; 95% CI, 0.14-0.48; p < .01), recurrence-free survival (HR, 0.40; 95% CI, 0.20-0.82; p = .01), metastasis-free survival (HR, 0.27; 95% CI, 0.15-0.46; p ≤ .01), and event-free survival (HR, 0.26; 95% CI, 0.16-0.41; p ≤ .01) compared with patients who had a partial (0%-99%) response.
CONCLUSIONS
Complete tumor necrosis should be the index parameter to grade response to treatment as satisfactory in patients with Ewing sarcoma. Any viable tumor in these patients after neoadjuvant treatment should be of oncologic concern. These findings can affect the design of new clinical trials and the risk-stratified application of conventional or novel treatments.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
60-70Informations de copyright
© 2022 American Cancer Society.
Références
Balamuth NJ, Womer RB. Ewing’s sarcoma. Lancet Oncol. 2010;11(2):184-192. doi:10.1016/S1470-2045(09)70286-4
Thacker MM, Temple HT, Scully SP. Current treatment for Ewing’s sarcoma. Expert Rev Anticancer Ther. 2005;5(2):319-331. doi:10.1586/14737140.5.2.319
Lahl M, Fisher VL, Laschinger K. Ewing’s sarcoma family of tumors: an overview from diagnosis to survivorship. Clin J Oncol Nurs. 2008;12(1):89-97. doi:10.1188/08.CJON.89-97
Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(33):4148-4154. doi:10.1200/JCO.2011.41.5703
Ganjoo KN, Patel S. The treatment outcome for adult patients with Ewing’s sarcoma. Curr Oncol Rep. 2013;15(4):372-377. doi:10.1007/s11912-013-0317-5
Bosma SE, Ayu O, Fiocco M, Gelderblom H, Dijkstra PDS. Prognostic factors for survival in Ewing sarcoma: a systematic review. Surg Oncol. 2018;27(4):603-610. doi:10.1016/j.suronc.2018.07.016
Miller BJ, Gao Y, Duchman KR. Does surgery or radiation provide the best overall survival in Ewing’s sarcoma? A review of the National Cancer Data Base. J Surg Oncol. 2017;116(3):384-390. doi:10.1002/jso.24652
Benjamin RS, Wagner MJ, Livingston JA, Ravi V, Patel SR. Chemotherapy for bone sarcomas in adults: the MD Anderson experience. Am Soc Clin Oncol Educ Book. 2015;35:e656-e660. doi:10.14694/edbook_am.2015.35.e656
Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49(6):1221-1230. doi:10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e
Rosen G, Caparros B, Groshen S, et al. Primary osteogenic sarcoma of the femur: a model for the use of preoperative chemotherapy in high risk malignant tumors. Cancer Invest. 1984;2(3):181-192. doi:10.3109/07357908409104370
Albergo JI, Gaston CL, Laitinen M, et al. Ewing’s sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response. Bone Joint Lett J. 2016;98-B(8):1138-1144. doi:10.1302/0301-620X.98B8.37346
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-349. doi:10.1016/j.jclinepi.2007.11.008
Tsuda Y, Tsoi K, Parry MC, et al. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma. Bone Jt J. 2020;102(6):795-803. doi:10.1302/0301-620X.102B6.BJJ-2019-1307.R1
Leavey PJ, Laack NN, Krailo MD, et al. Phase III trial adding vincristine-topotecan-cyclophosphamide to the initial treatment of patients with nonmetastatic Ewing sarcoma: a Children’s Oncology Group report. J Clin Oncol. 2021;39(36):4029-4038. doi:10.1200/JCO.21.00358
Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing’s sarcoma: National Cancer Data Base report. Clin Orthop Relat Res. 2007;459:40-47. doi:10.1097/BLO.0b013e318059b8c9
Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18(17):3108-3114. doi:10.1200/JCO.2000.18.17.3108
Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33(27):3036-3046. doi:10.1200/JCO.2014.59.5256
Palmerini E, Gambarotti M, Ratan R, et al. Graceful Project: a global collaboration on CIC-DUX4, BCOR-CCNB3, high grade undifferentiated round cell sarcoma (URCS) [abstract 3251212]. Paper presented at: 2019 Connective Tissue Oncology Society (CTOS) Annual Meeting; November 13-16, 2019; Tokyo, Japan. https://www.ctos.org/Portals/0/PDF/2019%20CTOS%20Final%20Program.pdf
Rekhi B, Kembhavi P, Mishra SN, Shetty O, Jyoti Bajpai AP. Clinicopathologic features of undifferentiated round cell sarcomas of bone & soft tissues: an attempt to unravel the BCOR-CCNB3- & CIC-DUX4-positive sarcomas. Indian J Med Res. 2019;150(6):557-574. doi:10.4103/ijmr.IJMR_2144_18